Skip to main content
SpringerLink
Log in

Amyloid PET Imaging: Standard Procedures and Semiquantification

  • Protocol
  • First Online:
Biomarkers for Alzheimer’s Disease Drug Development

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2785))

Abstract

Amyloid plaques are a neuropathologic hallmark of Alzheimer’s disease (AD), which can be imaged through positron emission tomography (PET) technology using radiopharmaceuticals that selectively bind to the fibrillar aggregates of amyloid-β plaques (Amy-PET). Several radiotracers for amyloid PET have been validated (11C-Pittsburgh compound B and the 18F-labeled compounds such as 18F-florbetaben, 18F-florbetapir, and 18F-flutemetamol). Images can be interpreted by means of visual/qualitative, semiquantitative, and quantitative criteria. Here, we summarize the main differences between the available radiotracers for Amy-PET, the proposed interpretation criteria, and main proposed quantification methods.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement 7:270–279

    Article  PubMed  PubMed Central  Google Scholar 

  2. Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13:614–629

    Article  PubMed  Google Scholar 

  3. Teipel S, Drzezga A, Grothe MJ et al (2015) Multimodal imaging in Alzheimer’s disease: validity and usefulness for early detection. Lancet Neurol 14:1037–1353

    Article  PubMed  Google Scholar 

  4. Teunissen CE, Verberk IMW, Thijssen EH et al (2022) Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol 21:66–77

    Article  CAS  PubMed  Google Scholar 

  5. Caprioglio C, Garibotto V, Jessen F et al (2022) The clinical use of Alzheimer’s disease biomarkers in patients with mild cognitive impairment: a European Alzheimer’s disease consortium survey. J Alzheimers Dis 89:535–551

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. van Dyck CH, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388:9–21

    Article  PubMed  Google Scholar 

  7. Mintun MA, Lo AC, Duggan Evans C et al (2021) Donanemab in early Alzheimer’s disease. N Engl J Med 384:1691–1704

    Article  CAS  PubMed  Google Scholar 

  8. Klunk WE, Koeppe RA, Price JC et al (2015) The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11:11–15

    Article  Google Scholar 

  9. Guerra UP, Nobili FM, Padovani A et al (2015) Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurol Sci 36:1075–1081

    Article  PubMed  Google Scholar 

  10. Minoshima S, Drzezga AE, Barthel H et al (2016) SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med 57:1316–1322

    Article  CAS  PubMed  Google Scholar 

  11. Garibotto V, Morbelli S, Pagani M (2016) Erratum to: dual-phase amyloid PET: hitting two birds with one stone. Eur J Nucl Med Mol Imaging 43:1747

    Article  PubMed  Google Scholar 

  12. Magistretti PJ (2000) Cellular bases of functional brain imaging: insights from neuron-glia metabolic coupling. Brain Res 886:108–112

    Article  CAS  PubMed  Google Scholar 

  13. Boccalini C, Peretti DE, Ribaldi F et al (2022) Early-phase 18F-Florbetapir and 18F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting. J Nucl Med 64:266–273

    Article  PubMed  Google Scholar 

  14. van Berckel BN, Ossenkoppele R, Tolboom N et al (2013) Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med 54:1570–1576

    Article  PubMed  Google Scholar 

  15. Collij LE, Konijnenberg E, Reimand J et al (2019) Assessing amyloid pathology in cognitively normal subjects using 18F-Flutemetamol PET: comparing visual reads and quantitative methods. J Nucl Med 60:541–547

    Article  PubMed  PubMed Central  Google Scholar 

  16. Oliveira FP, Ferreira SM, Silva MG et al (2022) Patlak plot based on the first 30 minutes post-injection dynamic 18F-florbetaben positron emission tomography scan separates amyloid-β positive from negative studies. Br J Radiol 95(1139):20211023

    Article  PubMed  PubMed Central  Google Scholar 

  17. Yoon HJ, Kim BS, Jeong JH et al (2021) Dual-phase 18F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer’s disease. Neuroimage Clin 31:102773

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ni R, Gillberg PG, Bergfors A et al (2013) Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain 136:2217–2227

    Article  PubMed  Google Scholar 

  19. Hsiao IT, Huang CC, Hsieh CJ et al (2012) Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging 39:613–620

    Article  CAS  PubMed  Google Scholar 

  20. Koole M, Lewis DM, Buckley C et al (2009) Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 50:818–822

    Article  CAS  PubMed  Google Scholar 

  21. O’Keefe GJ, Saunder TH, Ng S et al (2009) Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med 50:309–315

    Article  PubMed  Google Scholar 

  22. Chincarini A, Sensi F, Rei L et al (2016) Alzheimer’s Disease Neuroimaging Initiative. Standardized uptake value ratio-independent evaluation of brain amyloidosis. J Alzheimers Dis 54:1437–1457

    Article  CAS  PubMed  Google Scholar 

  23. Kinahan PE, Fletcher JW (2010) Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 31:496–505

    Article  PubMed  PubMed Central  Google Scholar 

  24. Thurfjell L, Lilja J, Lundqvist R et al (2014) Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med 55:1623–1628

    Article  CAS  PubMed  Google Scholar 

  25. Clark CM, Pontecorvo MJ, Beach TG et al (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 11:669–678

    Article  CAS  PubMed  Google Scholar 

  26. Landau SM, Thomas BA, Thurfjell L et al (2014) Alzheimer’s Disease Neuroimaging Initiative. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 41:1398–1407

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Bischof GN, Bartenstein P, Barthel H et al (2021) Toward a universal readout for 18F-labeled amyloid tracers: the CAPTAINs study. J Nucl Med 62:999–1005

    Article  CAS  PubMed  Google Scholar 

  28. Battle MR, Pillay LC, Lowe VJ et al Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. EJNMMI Res 8(1):107

    Google Scholar 

  29. Chincarini A, Peira E, Corosu M et al (2020) A kinetics-based approach to amyloid PET semi-quantification. Eur J Nucl Med Mol Imaging 47(9):2175–2185

    Article  CAS  PubMed  Google Scholar 

  30. Johnson KA, Minoshima S, Bohnen NI et al (2013) Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement 9:e-1–e-16

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, Italy

    Francesca D’Amico, Luca Sofia, Matteo Bauckneht & Silvia Morbelli

  2. IRCCS Ospedale Policlinico San Martino, Genoa, Italy

    Francesca D’Amico, Luca Sofia, Matteo Bauckneht & Silvia Morbelli

Authors
  1. Francesca D’Amico
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luca Sofia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matteo Bauckneht
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvia Morbelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvia Morbelli .

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Psychotherapy, LMU Hospital, Ludwig-Maximilians-University Munich, Munich, Germany

    Robert Perneczky

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

D’Amico, F., Sofia, L., Bauckneht, M., Morbelli, S. (2024). Amyloid PET Imaging: Standard Procedures and Semiquantification. In: Perneczky, R. (eds) Biomarkers for Alzheimer’s Disease Drug Development. Methods in Molecular Biology, vol 2785. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3774-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-3774-6_11

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-3773-9

  • Online ISBN: 978-1-0716-3774-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation